Pathogenic Advances and Therapeutic Perspectives for Eosinophilic Inflammation
With the recent approval of the first eosinophil-depleting therapeutic agents targeting the IL-5 pathway for treatment of severe eosinophilic asthma, eosinophils and eosinophilic disorders are in the limelight. Indeed, setbacks during clinical development of these compounds have revealed how much re...
Saved in:
Main Author: | Florence E. Roufosse (auth) |
---|---|
Other Authors: | Mats W. Johansson (auth) |
Format: | Book Chapter |
Published: |
Frontiers Media SA
2018
|
Subjects: | |
Online Access: | Get Fullteks DOAB: description of the publication |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Severe Eosinophilic Disorders: Mechanisms and Clinical Management
Published: (2019) -
Secretion of Cytokines and Chemokines by Innate Immune Cells
by: Paige Lacy
Published: (2015) -
Differentiation and Mechanisms of Activation of Innate Lymphoid Cells
Published: (2019) -
Asthma : Current Perspectives on Phenotypes, Endotypes, and Treatable Traits
Published: (2021) -
Mast Cells in Itch, Pain and Neuro-inflammation
Published: (2020)